These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2141516)

  • 1. CSF drug levels for children with acute lymphoblastic leukemia treated by 5 g/m2 methotrexate. A study from the EORTC Children's Leukemia Cooperative Group.
    Milano G; Thyss A; Serre Debeauvais F; Laureys G; Benoit Y; Deville A; Dutour C; Robert A; Otten J; Behar C
    Eur J Cancer; 1990 Apr; 26(4):492-5. PubMed ID: 2141516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
    Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate.
    Millot F; Rubie H; Mazingue F; Mechinaud F; Thyss A
    Leuk Lymphoma; 1994 Jun; 14(1-2):141-4. PubMed ID: 7920221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
    Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
    Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
    Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
    Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 7-Hydroxymethotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia.
    Borsi JD; Sagen E; Romslo I; Slørdal L; Moe PJ
    Cancer Chemother Pharmacol; 1990; 27(2):164-7. PubMed ID: 2249335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables.
    Seidel H; Andersen A; Kvaløy JT; Nygaard R; Moe PJ; Jacobsen G; Lindqvist B; Slørdal L
    Leuk Res; 2000 Mar; 24(3):193-9. PubMed ID: 10739001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies.
    Thyss A; Milano G; Deville A; Manassero J; Renee N; Schneider M
    Eur J Cancer Clin Oncol; 1987 Jun; 23(6):843-7. PubMed ID: 3477462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
    Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
    Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Investigation on individualized adjustment of target range of high-dose methotrexate].
    Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
    Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study on the pharmacokinetics of 7-hydroxy-methotrexate after administration of methotrexate in the dose range of 0.5-33.6 g/m2 to children with acute lymphoblastic leukemia.
    Borsi JD; Sagen E; Romslo I; Moe PJ
    Med Pediatr Oncol; 1990; 18(3):217-24. PubMed ID: 2329967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
    Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose methotrexate as part of remission maintenance therapy for childhood acute lymphocytic leukemia: a Pediatric Oncology Group pilot study.
    Frankel LS; Wang YM; Shuster J; Nitschke R; Doering EJ; Pullen J
    J Clin Oncol; 1983 Dec; 1(12):804-9. PubMed ID: 6583318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate.
    Refsum H; Wesenberg F; Ueland PM
    Cancer Res; 1991 Feb; 51(3):828-35. PubMed ID: 1988122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study.
    Camitta B; Mahoney D; Leventhal B; Lauer SJ; Shuster JJ; Adair S; Civin C; Munoz L; Steuber P; Strother D
    J Clin Oncol; 1994 Jul; 12(7):1383-9. PubMed ID: 8021728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma.
    Vassal G; Valteau D; Bonnay M; Patte C; Aubier F; Lemerle J
    Pediatr Hematol Oncol; 1990; 7(1):71-7. PubMed ID: 2397170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia.
    Donelli MG; Zucchetti M; Robatto A; Perlangeli V; D'Incalci M; Masera G; Rossi MR
    Med Pediatr Oncol; 1995 Mar; 24(3):154-9. PubMed ID: 7838036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of cerebrospinal fluid beta-glucuronidase activity with plasma methotrexate concentrations in leukemic children receiving high-dose methotrexate.
    Vlacha V; Eliopoulou M; Haidas S; Beratis NG
    Pediatr Blood Cancer; 2004 Apr; 42(4):350-6. PubMed ID: 14966832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.